
Sunny Singh
Masters Student in Aeronautics and Astronautics, admitted Autumn 2022
Bio
Howdy y'all! I'm currently pursuing an M.S. in Aero & Astro at Stanford and am passionate about Exploration, Education, and Community Service. I graduated from Georgia Tech with a B.S. in Mechanical Engineering with a minor in Computer Science (specializing in Automation & Robotic Systems).
Education & Certifications
-
Bachelors, Georgia Institute of Technology, Mechanical Engineering + Computer Science (2022)
-
Certificate, MathWorks, Simulink for System and Algorithm Modeling (2021)
-
Certificate, SolidWorks Training Center, Certified SOLIDWORKS Associate in Mechanical Design - CSWA (2018)
Work Experience
-
Automation & Controls Engineer, SpaceX (5/16/2022 - 8/19/2022)
Location
Brownsville, Texas
-
Hardware Development Engineer, Amazon Robotics (1/7/2021 - 5/1/2021)
Location
Boston, Massachusetts
-
787 Equipment Reliability Engineer, Boeing (5/1/2020 - 9/1/2020)
Location
Charleston, South Carolina
-
Radio Frequency R&D Intern, Avanos, Med Tech. (5/1/2019 - 8/1/2019)
Location
Atlanta, Georgia
All Publications
-
Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.
JAMA network open
1800; 5 (1): e2142046
Abstract
Importance: The COVID-19 pandemic has had a distinct spatiotemporal pattern in the United States. Patients with cancer are at higher risk of severe complications from COVID-19, but it is not well known whether COVID-19 outcomes in this patient population were associated with geography.Objective: To quantify spatiotemporal variation in COVID-19 outcomes among patients with cancer.Design, Setting, and Participants: This registry-based retrospective cohort study included patients with a historical diagnosis of invasive malignant neoplasm and laboratory-confirmed SARS-CoV-2 infection between March and November 2020. Data were collected from cancer care delivery centers in the United States.Exposures: Patient residence was categorized into 9 US census divisions. Cancer center characteristics included academic or community classification, rural-urban continuum code (RUCC), and social vulnerability index.Main Outcomes and Measures: The primary outcome was 30-day all-cause mortality. The secondary composite outcome consisted of receipt of mechanical ventilation, intensive care unit admission, and all-cause death. Multilevel mixed-effects models estimated associations of center-level and census division-level exposures with outcomes after adjustment for patient-level risk factors and quantified variation in adjusted outcomes across centers, census divisions, and calendar time.Results: Data for 4749 patients (median [IQR] age, 66 [56-76] years; 2439 [51.4%] female individuals, 1079 [22.7%] non-Hispanic Black individuals, and 690 [14.5%] Hispanic individuals) were reported from 83 centers in the Northeast (1564 patients [32.9%]), Midwest (1638 [34.5%]), South (894 [18.8%]), and West (653 [13.8%]). After adjustment for patient characteristics, including month of COVID-19 diagnosis, estimated 30-day mortality rates ranged from 5.2% to 26.6% across centers. Patients from centers located in metropolitan areas with population less than 250 000 (RUCC 3) had lower odds of 30-day mortality compared with patients from centers in metropolitan areas with population at least 1 million (RUCC 1) (adjusted odds ratio [aOR], 0.31; 95% CI, 0.11-0.84). The type of center was not significantly associated with primary or secondary outcomes. There were no statistically significant differences in outcome rates across the 9 census divisions, but adjusted mortality rates significantly improved over time (eg, September to November vs March to May: aOR, 0.32; 95% CI, 0.17-0.58).Conclusions and Relevance: In this registry-based cohort study, significant differences in COVID-19 outcomes across US census divisions were not observed. However, substantial heterogeneity in COVID-19 outcomes across cancer care delivery centers was found. Attention to implementing standardized guidelines for the care of patients with cancer and COVID-19 could improve outcomes for these vulnerable patients.
View details for DOI 10.1001/jamanetworkopen.2021.42046
View details for PubMedID 34982158